MedPharm has added a first-to-file generic topical product to its commercial manufacturing portfolio. Under the agreement, MedPharm will serve as the commercial manufacturing and supply partner for the product.
The agreement is the company's sixth commercial deal secured in the last 22 months. It also builds on MedPharm's nearly three decades of specialization in topical and transepithelial drug products.
The deal expands MedPharm's capabilities into first-to-file generic topical drug products. The product will be manufactured at the company's 110,000 sq. ft. commercial manufacturing facility in Durham, North Carolina, which combines specialized manufacturing and analytical capabilities, purpose-built infrastructure and an experienced team to support commercial production and supply of topical drug products.
CEO Bill Humphries said the agreement is another significant milestone reflecting the business's escalating growth, and that adding a first-to-file generic topical product to its commercial portfolio reflects the breadth of programs the company can support and the value of its specialized expertise in topical drug products. He said the MedPharm team looks forward to supporting its partner through commercial manufacturing and supply.
The product name and partner were not disclosed.